`
`'-;-arfi'§
`
`'
`
`1
`
`'
`{3‘
`
`
`
`-;-‘I
`
`‘
`'*
`"fir-'1'
`
`5} mi.)
`If
`a:
`"New;
`i
`1’"
`J,
`:1
`
`"w"
`Egg)
`33'?!
`.
`'~:
`"5-.
`n gt,
`km"-
`"1w
`
`
`
`”"15? "5
`q
`“
`-'
`-
`,
`«aw
`
`$5.
`7."
`’5’
`‘
`-.,
`
`.
`
`'
`
`P0162
`
`
`
`AM NEAL
`
` AMNEAL
`
`PHARMACEUTICALS
`
`'
`
`AMNEAL 1021
`
`
`
`1
`
`
`
`LABORATORY NOTEBOOK
`
`LABORATORY NOTEBOOK GUIDELINESt
`
`l't9TEBOOK_~_Q~___2_,D"---L'16"-=2-_______________________________ ~---------
`
`CONTINUED FROM NOTEBOOK NO.
`
`CONTINUED TO NOTEBOOK NO.
`
`ASSIGNED TO:
`
`SIGNATURE
`
`DATE
`
`'
`
`PATE ISfi!lm _____ __ll[__,__!---'Lt_,__/-'=2,o'-'-'l3--.· - - - - - -=Bv _ __(WyA ___________________________________________ _
`
`---------------~~~~~~
`
`PHONE
`
`Q..QMl'fl_lll_y _____ _
`
`DEPARTMENT
`
`AD_t;JRESS
`
`
`~~~~------------------------- --------------------·
`
`--------------------~~~-
`
`QJTY ----------------------------------- -~-
`
`STATE
`
`Z~I~P ______________ _
`
`NOTES:
`
`____ NWM_Il!;B_OF PAGEs.ELL.Lf:.Qli'L ____________________________________ _
`
`www.vwr.com
`
`VWRCl!7
`INTERNATIONAl
`
`LABORATORY NOTEBOOK INTRODUCTION
`Using a Laboratory Notebook to record ideas, inventions,
`experimentation records, observations and all work details is a
`vital
`part
`of any laboratory process. Careful attention to how you keep
`your Laboratory Notebook can have a positive impact on the
`patent outcome of a pending discovery or invention.
`Following are some overall recommendations to help you keep
`more efficient and accurate Laboratory Notebook entries.
`Remember, however, that these are simply a suggested set of
`guidelines. Only your attorney can supply the exact guidelines
`she would like you to follow to satisfy specific legal require(cid:173)
`ments. That is why we recommend that you consult your legal
`counsel.
`
`RECORDING DATA
`Your Laboratory Notebook is a vital record of your work whether
`it is for patent purposes, legal records or documenting drug
`research under FDA guidelines. The Laboratory Notebook can
`help you prove:
`a. Exact details and dates of conception
`b. Details and dates of reduction to practice
`c. Diligence in reducing your invention to practice
`d. Details regarding the structure and operation of your
`invention
`e. Experimentation observations and results
`f. A chronological record of your work
`g. Other work details
`
`Follow a few simple rules of thumb
`1. Always record entries legibly, neatly and in permanent ink.
`2. Immediately enter into your notebook and date all original
`concepts, data and observations, using separate headings
`to differentiate each.
`3. Record all concepts, results, references and other infor(cid:173)
`mation in a systematic and orderly manner. (Language,
`charts and numbering systems should be maintained con(cid:173)
`sistently throughout.)
`4. It is acceptable to make your entries brief. Always, howev(cid:173)
`er, include enough details for someone else to successful(cid:173)
`ly duplicate the work you have recorded.
`5. Label all figures and calculations.
`6. Never, under any circumstances, remove pages from your
`notebook.
`
`Remember to treat your Laboratory Notebook as a legal
`document: It records the chronological history of your activi(cid:173)
`ties. The following guidelines should help you maintain the con(cid:173)
`sistent and accurate entries needed for future legal purposes.
`1. Start entries at the top of the first page, and always make
`successive, dated entries, working your way to the bottom
`of the last page.
`2. After completing a page, sign it before continuing to the
`next page.
`3. Make sure that you record the date of each entry clearly
`and unambiguously.
`4. Never let anyone other than yourself write in your
`Notebook (excluding witness signatures, discussed later).
`
`5. Never leave blank spaces, and never erase or remove
`material you have added. Simply draw lines through any
`blank spaces at the same time you are making your
`entries.
`6. Do not erase errors. Just draw a single line through any
`·erroneous entry, then add your initials. Enter the correct
`entry nearby.
`7. You can supplement your entries with supporting material
`(e.g., test-result printouts and other documentation). But
`you must permanently affix the material onto a page in its
`proper chronological location.
`8. Never rely solely on any supplemental attachment. Always
`include your own entry describing the attachment and add
`any conclusions that you might draw from its substance.
`9. Occasionally, secondary sources might be too large or
`inappropriate to attach directly to your notebook. In this
`case, you can add all secondary sources to an ancillary
`record maintained precisely for this purpose. However,
`always remember to write a description of these second(cid:173)
`ary sources, clearly and unambiguously, in your notebook.
`
`DOCUMENTING PATENT ACTIVITIES
`A primary purpose of a Laboratory Notebook is the support of
`documenting work that may be patentable. To support patent
`activities, it is necessary to provide clear, concise, chronologi(cid:173)
`cal entries with specific dates. To rely on these dates, you must
`have at least one non-inventor corroborate that the events
`actually happened and that he or she understood your inven(cid:173)
`tion by signing and dating the "Disclosed to and Understood by''
`signature blocks.
`Your Laboratory Notebook should help you document and
`prove:
`1. Conception Date-The date that you knew your invention
`would solve the problem.
`2. Date of reduction to practice-The moment that you made
`a working embodiment of your invention.
`3. Diligence in reducing your invention to practice-Diligence
`refers to your intent and conscious effort to make a work(cid:173)
`ing embodiment. You are not required to rush, or even to
`take the most efficient development strategy. But your
`Notebook must include details relating to your diligent
`activities. These are dates and facts that show what activ(cid:173)
`ities you have conducted to reduce the invention to prac(cid:173)
`tice, and when such activities were conducted. Since you
`may still be diligent despite periods of not working on
`reducing your invention to practice, always remember to
`provide reasonable excuses for these periods of inactivity
`by supplying facts relating to why there was no activity
`during the period in question. (e.g., unavailability of test
`conditions or equipment).
`4. How to make and use your invention-provide documen(cid:173)
`tation details sufficient to teach a colleague how to make
`and use your invention.
`5. The best mode of practicing your invention-document the
`best way to practice your invention.
`A non-inventor colleague should corroborate each of these
`events/facts by signing the "Disclosed to and Understood by"
`on the relevant pages.
`
`t VWR provides these sample guidelines "AS IS" without any
`warranty.
`
`[69005-130V02 Sep·2005]
`
`2
`
`
`
`TABLE OF CONTENTS
`
`~
`
`1
`
`3
`
`flx""'""'"~\""''~"' Hr I
`'T
`<J
`2 o~.
`cr
`
`(JIJ 1-,.,.r.-_\pt-<J.
`
`- \ ' ' ' ' " &
`'I
`
`\-10 I ~ \() h>."'l ~!"L
`
`~IIR I~"T
`
`Lot -://'
`M~:~~;.~.:t.:) fDI&l~~i
`PDl6 ~~~
`
`()•.,_<ll'lf •• "''"'"'
`LfiHt•$ )
`
`Poa~ 1/1/J •
`s _,o
`
`~
`
`DATE
`
`II /tt_, J.t '::..
`
`11-t?.
`
`14/U'>Ii-3
`
`.
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`29
`
`30
`
`31
`
`32
`
`3
`
`
`
`TABLE OF CONTENTS
`
`TABLE OF CONTENTS
`
`PAGE
`
`!':1 IRI<'I"'T
`
`DATE
`
`PAGE
`
`<:IIR.Iei"'T
`
`DATE
`
`33
`
`34
`
`35
`
`36
`
`37
`
`38
`
`39
`
`40
`
`41
`
`42
`
`43
`
`44
`
`45
`
`46
`
`47
`
`48
`
`49
`
`50
`
`51
`
`52
`
`53
`
`54
`
`55
`
`56
`
`57
`
`58
`
`59
`
`60
`
`61
`
`62
`
`63
`
`64
`
`'
`
`j
`
`.
`
`65
`
`66
`
`67
`
`68
`
`69
`
`70
`
`71
`
`72
`
`73
`
`74
`
`75
`
`76
`
`77
`
`78
`
`79
`
`80
`
`81
`
`82
`
`83
`
`84
`
`85
`
`86
`
`87
`
`88
`
`89
`
`90
`
`91
`
`92
`
`93
`
`·94
`
`95
`
`96
`
`4
`
`
`
`TABLE OF CONTENTS
`
`TITLE
`
`'P-
`
`.
`
`•
`
`•
`
`PROJECT
`'
`
`. . :
`
`BOOK
`
`[
`
`[ . •
`
`; I
`
`£'[1_(3!= _____ ---------------------- ----- - -------
`97
`
`DATE
`
`98
`
`102
`
`107
`1---------+··-··---··-···---------------
`108
`
`- - ---------------- . -- --------------------------·--·-·-- --- - -- --
`
`- --- ----- ---------- - - - -- --~---- ---
`
`1----- -+-- -----------------------· -· -·----- --------· --· ---·-·--· ·--·-· -·
`111
`
`---- ---------- --- - ------------------- ---------·-·----!---- -------------------·-
`
`112
`
`115
`
`1-- -- -+--------------------------------- ----------------·. ·-. -·-·- ------.. -· -----· -·-· ---· -· -·---· -·--
`
`'----
`
`1---
`10
`-
`---·-
`----· ----
`
`-~
`
`151-
`
`__ , ---'
`I
`l
`I :
`l
`20 -~ i
`
`privileged/confidential/attorney work product.
`
`--4
`
`·---,
`
`.
`
`'
`
`- --- ----- - --------- -- - --- ---- -- - -----··-··-··-··- -- ---------------
`
`40
`
`--·- _;_ ·- ··~'---"~-~ "--~ ~ _;~ """" ~
`
`""-""-"-": -- -: ---
`
`·--·····.:.,. .... ~ ...... .;. ...... :.. ...... .
`
`---- -·. ·-·-·- -- -· -·. ·-·- - -- ----. --·--· -· . ·--- -, __ . ·-.. -·-·--·---- -- -------------· -·- -- --------------- --------- --- ---- --·- ···! ------·-·--· .. ---· ----------·-.
`
`45
`
`'
`SIGNATURE
`
`•
`
`DATE
`
`i
`
`PROPRIETARY INFORMATI
`
`5
`
`
`
`November II, 2013
`
`To:
`
`Anita Kumar
`
`From: Dr. Tony Palmieri
`Dr. Vivian Gray
`
`Re:
`
`Endo Pharms., Inc. v. Amneal Pharms., LLC, Case No. I :12-cv-8115 (S.D.N.Y.)
`Formulation and Testing Protocol of Controlled-Release Oxymorphone Tablets
`
`The following memorandum sets fmth a protocol to formulate controlled-release
`oxymorphone hydrochloride as disclosed in WO 01/08661 A2 (Maloney) and to conduct in vitro
`dissolution testing of sample batches under the conditions detailed in U.S. Patent Nos. 8,309,122
`and 8,309,216, which are recited below. As you prepare and test these tablets, please be sure to
`record any variables (e.g., air compression) that you may need to adjust but are not explicitly
`noted below. Retain copies of documents and information generated during the manufacture and
`testing of the sample batch, including but not limited to lab notebooks, batch records, and
`calibration curves.
`
`I. Create Sample Batches of Controlled-Release Tablets Containing Oxymorphonc
`Hydrochloride
`
`Subparts A and B outline the formulas and steps required to formulate and
`manufacture two batches of at least I ,000 controlled-release tablets each.
`
`A. Formula #1
`
`The formula for the first sample batch of controlled-release tablets should include the
`following ingredients by weight:
`
`INGREDIENT
`
`AMOUNT
`
`Oxymorphone hydrochloride
`
`30 mg (20% w/w)
`
`Lactose, NF (Fast Flo)
`
`Amber lite IRP 69M Fine
`Pmticle Size
`
`Methocel KIOOM (Premium)
`CR
`(hydroxypropylmethylcellulose,
`USP)
`
`39.5% w/w
`
`5.0%w/w
`
`30.0%w/w
`
`Cab-0-Sil (M-5)
`
`0.5% w/w
`
`- 1 -
`
`Stearic Acid, NF (Powder)
`
`Theoretical Tablet Weight
`
`5.0%w/w
`
`150 mg
`
`B. Formula #2
`
`The formula for the second sample batch of controlled-release tablets should include the
`following ingredients by weight:
`
`INGREDIENT
`
`AMOUNT
`
`Oxymorphone hydrochloride
`
`30 mg (20% w/w)
`
`Lactose, NF (Fast Flo)
`
`Amberlite lRP 69M Fine
`Particle Size
`
`Methocel K!OOM (Premium)
`CR
`(hydroxypropylmethylcellulose,
`USP)
`
`Cab-0-Sil (M-5)
`
`Stearic Acid, NF (Powder)
`
`Theoretical Tablet Weight
`
`24.5%w/w
`
`5.0%w/w
`
`45.0%w/w
`
`0.5%w/w
`
`5.0%w/w
`
`150 mg
`
`C. Manufacturing Steps
`
`In manufacturing the sample batch of controlled-release tablets, please follow_ these steps
`in order. Please Jet us know immediately if you need to devmte from these steps m any
`manner.
`
`Obtain Amber lite JRP 69M Fine Particle Size. If Fine Particle Size is not
`)
`available, ~ease process the Amberlite by passing it thro~gh a 325 mesh _(U.S._ Standm:d
`mesh size) or by using other conventional methods to ach1eve a mean pa1t1cle s1ze that IS
`about 27 ]lm, or at least less than 44-50 ]lm.
`
`b)
`
`c)
`
`d)
`
`Pass Lactose NF (Fast Flo) through a No. 20 mesh screen for delumping;
`
`Mi II the Lactose;
`
`Pass the Cab-0-Sil (M-5) (a glidant), oxymorphone hydrochloride USP
`and Amberlite IRP-69M fine pa1ticle size through a No. 20 mesh screen
`for delumping and mix with the lactose for I 0 minutes to create a drug
`powder blend;
`
`- 2-
`
`6
`
`
`
`e)
`
`f)
`
`g)
`
`h)
`
`i)
`
`(Methocel Kl OOM
`the hydroxhypropylmethylcellulose USP
`Pass
`(premium) CR) through a No. 20 mesh screen for delumping;
`
`Then add the drug powder blend and mix for 20 minutes;
`
`Pass stearic acid NF (powder) through a No. 40 mesh screen and add to
`the batch;
`
`Then mix the batch for 5 minutes;
`
`Then compress the final blend to form tablets using a conventional tablet
`press and conventional tooling to form tablets of conventional hardness for
`extended-release dosage forms.
`
`II.
`
`Testing of Dissolution Rate of Sample Batches Created in Step 1
`
`The steps below outline in vitro dissolution tests, using six samples from each batch
`created in prut I. For the "USP Paddle Method," see Attachment A at§ 711, Dissolution for
`explanation on the parameters of the USP Paddle Method.
`
`Please perform the following in vitro dissolution testing method: USP Paddle
`in vitro
`Method at 50 rpm in 500 mL media at 37° C. Please perform the
`dissolution test using three different pH levels: 1.2, 4.5, and 6.8.
`
`For each tablet and pH tested, measure and record below the release of
`oxymorphone hydrochloride (in milligrams) at hours: I, 2, 3, 4, 5, 6, 8, 10, and
`12.
`
`Time (Hr)
`
`pH
`
`Oxymorphone Hydrochloride
`released into the solution (mg).
`
`I
`2
`3
`4
`5
`6
`8
`10
`12
`
`Again, please retain copies of documents and information generated during this expert,
`including but not limited to lab notebooks, batch records, and calibration curves.
`
`- 3 -
`
`TITLE To PeA~ ·rrn
`
`PROJECT 0 :X ~yp/;WYV 1-1.0
`
`- 5
`BOOK
`PAG
`'e.R- 1-etbldJ. DAl
`
`10~:tttteii16ll~~~tt.:t:t~t=;~:I:I:t::~s1:t:J;;I1itt!:::tt:-t:t:&J:kt::~:_:;:::ttj
`
`"~~ 0
`
`-·-:---
`
`______ j ________ ; ______ L __________ ~-------'--------~-----------1--------~ -----J __ -- ----!----------j ________ j _____ i_--~-------~------~--------L .......... t.
`
`l __ ..l_ __ j ___ j __ j _______ , _____ j _______ ~----- . ------~--- ·--...l------...1---··-··-···l-
`
`·~tt=t:!~~QJ:t1:::tJ-+- .. Jft:b::L:~:io:~i:k4Ji2t::~:O~.d~J::
`40 __ L_L__l _ ___i ___ l____l__L_ __ L_ _ _L LLL .. L_j __ _l __ _.__ __ ~ __ _L_L ... L .. LL_,__. L ... L
`:·t:~j:~~~tj~=t:t~t~L~+~~ftf~,~fJzt::J.::cT~l~~:=:
`
`-----~
`_____ J _____ ..J_ ______ -~., __ L _____ ; ______ _j ____ j ___ j _ --~---J ____ L_ __ J ___ j ______ ~ ---L---·-··-i ____ L __ ~--___ !-------L--------~----~-----L-----~------L- --~--- _
`_ ____ ,.
`__ j ____ _j_ ___ ,J ______ : _______ .i_ ___ i _____ ; _____ L ____ L_ ______ L_ ______ L_ ____ !. ___ L_, ____ ;_ ____ ._ ____ ; ____ _; __ J.._ _________ L_ ___ L ______ L_ ___ L __ L_~---_ _:._ _______ ;_____ . ________ , ______ , ___ _,__ ______ ._ ______ ; ________ ;_ --..., ______ L _____ ;___ ___ _i __ ~----~
`
`_____ ;..
`
`____ ,
`
`·----!
`
`_____ j
`
`PROPRIETARY INFORMATim
`
`7
`
`
`
`-\JPl6 }L • 6
`BOOK
`PAGE
`TITLE 'fo
`
`PROJECT Ox
`
`\'YIJ9Yl'kon-.
`
`I-!.Cl
`
`'U[I'til3
`~jQ 1-ei.btd:!: DATE
`
`ruto OL
`BOOK
`
`• 7
`PAG
`
`10
`1---!---!-
`
`15
`
`10
`1---~'---i
`
`25
`
`. . . i ' ~ . ..
`
`.
`
`_,.· ...
`
`_,. : .. -
`
`. .'-
`
`-·---'------··
`
`; ~ .
`
`---i--·----
`
`i __ c~L_L~~:~:~==-~:~~~ ~~: _ _:_ __ _~
`
`;
`:
`:
`.
`-
`-
`-
`:
`!
`-
`____ L __ ,_ ___ L ---.. ;.. -·-- ~--·---~----;------~·-· -· -~·-·-------- -~--- ~ -- -~
`
`~
`
`8
`
`
`
`PD I& 2... • 8
`
`BOOK
`PAGE
`TITLE To fv,to,.,.,rn
`
`PROJECT
`
`TITLE
`
`BOOK
`
`PAGE
`
`DATE
`
`I
`
`45
`
`\jY''g i;ufvtP(cid:173)
`
`oiSCt:osED-TOANDUNo-ERSTOODBY- ~ ---- ------- --- ---
`
`DATE
`
`40
`
`45
`
`SIGNATURE
`
`PROPRIETARY INFORMATION
`
`DISCLOSED TO AND UNDERSTOOD BY
`
`PROPRIETARY INFORMATION
`
`9
`
`
`
`nJ 10 'I- -
`BOOK
`
`IU
`PAGE
`
`-
`
`-
`
`J
`
`.......
`lCJ
`BOOK
`
`.1..1.
`PAGE
`
`25
`
`30
`
`40
`
`45
`
`. '
`
`\ 1\151'3
`~~-~ ~-~~~~~~~ ~~~-------~,~ ,,-,-, ~-~ ~-- -~~~~-~~~-~-~~~~~-~ -+ ··~-~~~-- ~ ~~---·. -~ ~ ~ ~~~~ ~~~ -~~~~~~ ·-
`. liht/~
`PROPRIETARY INFORMATION
`
`DATE
`
`45 ---______ .:._ __ ,~---------------- ------~----~-------------
`
`8':~_::~~~~~~~~~~~~ ~~~~~~~~~ ~~ij~ ~~~ ~~~ ~~~~~~--~~~-~~~ ~-~~-~
`i DATE h
`•
`!;
`-·
`.
`~~ IL
`
`DISCLOSED TO AND UNDERSTOOD BY
`
`~~~~~~~~~~~~~~,~ -~~~~~-~~~~~~~s-1 ~~-~~~~~~~
`
`PROPRIETARY INFORMATIOI\
`
`~~~~~~~~~
`
`~
`
`10
`
`
`
`\'D 16 2.-
`BOOK
`
`12
`TITLE tD p e.M-o'fY\"
`
`PAGE
`
`5
`
`10
`
`15
`
`20
`
`25
`
`30····~~
`
`------:'\7-----
`
`35
`
`45
`
`DISCLOSED TO AND UNDERSTOOD BY
`
`'LI r 15/1"'
`DATE
`
`TITLE lo
`
`I U l() 2--
`
`BOOK
`
`l,.j
`PAGE
`
`DATI
`
`10
`
`30
`
`40
`
`. ·-------:----- -·-----·-------- ----- -----------;-- ----- ------------;-- -·
`
`.
`.
`.
`.
`.
`.
`.
`.
`···-·-·- - -·- -- -- ·- - - ---·-·- --·-·····-······:-----·--·>··---------·- ----- _._ -------; ······-·- --- ~---------~------- ----------,-------
`
`..•. -·- -·- - --. --~ ---.' ·- -·--·------· ··------- . ---------- ---·--- -·---
`.
`.
`
`'
`
`------ --------- -----__ _: ______ : ___ _:__ ----- ~ --- ··- ...... ·--. -·- ------------- --- ----- -
`·siGNATURE------------·--.--------------------------·-·-·----------------·-----~----- ------------- -----
`!J"i\'9\pl~
`l\l\.;'\0
`. ~~~- --- -~----.... _- -~ ·~ -----. ~~--·- -~--... --~-------~--- i--·---·· ·~~ -· .. --.. -~· ....... ~~ ~--. . ·- -~ ... ~ .. ~-..... ~~~ ...... -- ~·
`DATE I I
`II.<;(;~
`PROPRIETARY INFORMATION
`
`DATE
`
`__ ---------··-·-9~n_~~!!~~-~~EE!f!.~---~
`
`45
`
`SIGNATURE
`
`DISCLOSED TO AND UNDERSTOOD BY
`
`~~-~ -· ------------rDATE________________ ---------------------------~--- -----·- --------------------------------- ---------------------·
`PROPRIETARY INFORMATION
`'
`lj I
`;
`.
`1-<.t //]
`
`11
`
`
`
`f'Dlb'L.;. 14
`
`. If I 1Gl13
`BOOK
`PAGE .
`•
`TITLE \D ~'fYVL c(.,t'so;oluh'Dn sh;d..1 PROJECT 0 :XtiiYW'Yf'~V!e i-ecJ 8n. 1-ei.b(,er DATE
`£01Jt~n_~~ci!'~'!'.E~9• --~HL~ ... _ '- ___ ! __ ' --=-----------+ --~-------·--- ___ ___ __ : .... ' ...... _ . ~-... _ ~j _ _!___LL. ··--'--- ____ ..
`···-·-·····---·---· -----··-· ------- ------ ·- -·----------·------------· ·-. -. ---- ........... -· . -·-...... -. . .. ----.. ~ ""'~"'\'= ~---------. ... . . .. . . -·--~--.
`System Suitability Summary Results
`cY),..\'l
`,,'
`.
`Name: Oxymorphone HCI
`
`-
`
`5
`
`10
`
`1
`
`2
`
`3
`
`Sarrpk> Narre
`
`Beg std pH6.8
`
`Beg std pH6.8
`Beg std pH6.8
`
`Beg std_pH6.B
`Beg std_pH6.8
`
`4
`5
`Mean
`.... ·-··-+-------·-
`15 Std. Dev.
`%RSD
`
`'
`
`'
`
`.
`
`.
`
`.
`
`'
`
`'
`
`Narre
`
`Rf
`
`Area
`
`Oxymorphone HCI
`Oxymorphone HCI
`
`Oxymorphone HCI
`Oxymorphone HCI
`
`1
`
`2.269
`
`2.270
`2.270
`
`2.270
`
`1909143
`
`1907697
`1907454
`1907688
`
`USP
`Rate
`Count
`
`9547
`
`9551
`9546
`9528
`
`LISP
`Tailing
`
`1.1
`
`1.1
`1.2
`1.2
`
`Oxymorphone HCI
`
`1.2
`9509
`1907001
`2.269
`1.2
`9536
`1907797
`2.269
`-----+---0-.00·1·--l-8-0-3.-8-76-l---+-- ....
`--t---
`
`0.0
`' '
`' ' j
`
`0.0
`
`•
`
`•
`
`:·
`
`'
`;
`
`. ' '
`
`'
`
`•
`
`'
`
`1'\ )
`
`I
`l
`'
`!
`'
`:
`; -+, --! . t +- +- +·····'····-··' ,,--·---•----c
`
`'
`
`.
`
`;
`
`'
`;
`
`I
`i
`'
`i
`
`'
`
`i
`T
`
`:
`
`.
`
`' '
`
`,
`
`'o A
`
`'
`,
`
`!
`
`. I
`
`·•.
`
`!
`
`TITLE f"o p~'YW\..
`
`ru 'b~ _ 15
`BOOK
`PAGE
`'i:R J-e.bDATI
`.
`
`•
`
`•
`
`: i
`
`•
`
`.
`
`•
`
`.,.
`
`: i I
`. '
`
`I
`.
`
`i
`
`•
`'
`;
`l '
`.
`'
`System Suitability Summary Results
`5 __ _ .,... _ __ _ __ _ __ __ I'IN<IIam~e::_~Ot'x<yv_!!lmi<JO"JrD!J.!Ih!'o~n'-"e'-'H="C"-'1-,---~----,--------;-;;;;;--,--~:
`LISP
`LISP
`J /
`Plate
`Tailing ~
`Count
`
`Sa!Tllle Narre
`
`Name
`
`RT
`
`Area
`
`1.1
`Oxymorphone HCI
`Beg std pH6.8
`1
`2.269
`~~-+--------~~~--------~-~
`~--
`1.1
`2
`Beg std pH6.8
`Oxymorphone HCI
`-
`2.270
`1907697
`9551
`_..J------B..::.e-:..g..::.st..::.d:=p_H_6_.8 ____ -I-o--'xy'-m-o_rc..ph_o_n_e __ H_C_I +--2-.2-7-~0-t--:1-:-9~o7=-4~5=4T9546 + 1.2
`10 I-_:_
`[-
`3
`~~~----~~~----~~~==~~~~~~~~=2~~1~24-
`4
`Beg std pH6.8
`Oxymorphone HCI
`2.270
`1907688
`95 8
`.
`~~~----~~~----~~~==~~~~~~~~~~--
`5
`Beg std pH6.8
`Oxymorphone HCI
`2.269
`1907001
`9509
`1.2
`..
`· __
`6
`Mid std-1
`Oxymorphone HCI
`2.270
`1903938
`9459
`1.2
`..
`.
`--t--- -+--------
`- -
`15 - - - - - - - - - - - - - - - - - - -1 - - - ·
`.f-_7__ __ __ Mid std_:_1__ __ __ Oxymorphone HCI_I2.272
`1903100
`9470
`. 1.2_--·
`1901373 -~4~6 ~--
`__ ___fllli_d_std-2
`__ __
`Oxymorphone HCI
`2.272
`·
`· 8
`- t -
`..
`-~
`f - - - - -+ - -
`·
`9
`Mid std-2
`Oxymorphone HCI
`2.273
`1901510
`9470
`1.2
`
`1909143
`
`9547
`
`"_ 10=-~~· Mi~ std-3 = = -f-Oxymorpho_ne HCI ~ _z.:_n3-l_1899934_-~94_70 -_j--~2 _':
`
`20
`
`25
`
`. __ 1_1_ f - - - - - - Mid std-~ _____ · Oxymorphone HC~ ~-_3.274 -++900~~7!)_!+- 1_2_.
`OxymorphoneHCI ~~2~ ~96~4 9453_1-1.2_··
`__ 12 _
`_ __ Midstd-4_ __
`~-
`13
`Mid std-4
`Oxymorphone HCI
`2.275
`1 189_9653
`9483
`1.2
`. -M ----- End std- - - - - Oxymorphone HCI. +- 2.274--1898745 --9465 12"
`· .. - - - - - - - - ·
`· - - - - - - - , - - - - - -..
`15
`End std
`Oxymorphone HCI
`2.274
`1899490
`9477
`1.2
`..
`.
`- - - - - - - - - - - - - - -
`- - - - - . - - ·-1-- - - - 1 - - - - - - - -
`.Mean
`2.272
`1903127
`9492
`1.2
`..
`~td.Dev.:_____ ____
`% RSD
`
`- - - - - - - - - - - -
`
`- - - - - - - - - - - - - - - - - - - - · - - - - - - - - - · - - - - - - - - -
`
`'
`'
`'
`l ! - --'
`'
`i
`'
`' l • '
`.a!~ ~ J
`~ 1 o' 1~.~ 'h 1
`:::::~f~E" ~±
`20 :::•±±··•··
`.
`.
`; ( tJ l.-1 ~ C)
`() : ()
`·.· ·-,·. --=--~~f.Ki¥5
`---
`.
`. .
`. •.
`.
`. .
`'
`;
`25 f---i-+ +--· ,'_·- -·'·"···+-: t.:clJ•·+ r,··rri-··hh·-,h;·+.·-.·,·1~--+_··-··-':·_···+r·--+·:l' ·i + ·J-+-~-t--1-,'-.. -.2.:+_,-.d)·•~--_+
`__ ,, __ -_',·_-_-_ :~··:~.t~- ::~.:.i::.::_:::::----_· .:·::::,==~=:!=--=~~-=:
`-c "; J:.c:
`'--!-;!---·-····'········'-·-'---'-+ -+---'---1
`, ;;,-:;or--·
`..
`.:.;·
`-· ·_
`,
`'
`;
`'
`'
`.
`'
`.
`.
`.
`, ___ ,_
`, :tn,-c>
`' o ,.. t-.
`'~
`Ei-t l-i.._ ... --.. "".":! .... !±J,) ... J.:.i£DO~'-Jl .... i ... L• ·······-------'--···•·---·---·+·-1
`' : .
`.
`'
`,
`'
`I
`- ~
`.
`- -
`-
`I
`' •
`'
`1--+---+---+-::::::t:::h-
`.
`:
`' ' T '
`.. ' .... ;c·· -··'········+ •· ...... ;•. +·+ ·+···!···+--';-····· :··· .... ; ....................... , ..... -+-··L
`·1
`,
`,
`'
`.
`' :
`: '
`i ·
`'
`.---... ~ ,i;
`.---·:··--·----+,--···•·--·· ,·----·----:!•·-·+·---;---I
`i
`:
`:
`l ;
`. • ' l
`• : ' ;
`!
`!
`.................... +- -+--+-+-L •. ····• ,---.·----,-+---L,, -t,--1
`!----
`T
`; 1..)-U,:,
`.
`!
`i
`;
`.
`!
`'
`~--+·+-+--t--+---f,_- -~,-+-+-·+:,· -+:·++--·L ...•.. ,~jV·ho/.·'~/~,--++-!-~-~~~---i,--+.--·++---!:-l·····}---·+,--+---+i':··-.--~---L---~--1
`"F-:.[+. -~---+--·!·--+--·+·-··! ~-·--·+ ··'-,--'.----'---~----i---i---1
`,
`, -.u-f'
`!
`
`30 ···t r· -T··---~ - _J
`
`'
`
`t
`
`!
`
`N
`
`35
`
`j
`
`;
`
`I
`
`!'
`
`40
`
`i
`j
`
`l
`;
`
`;
`
`:_ , !._ ·-+- +·-+·- ~---:' ........ ;·.
`i
`•
`'
`[
`
`+
`
`.
`
`'
`-······',,--... L
`
`i
`
`'
`
`:
`
`i
`
`i
`
`i
`
`i
`
`i
`
`i ' i
`
`i
`
`i
`
`:
`
`-
`
`;
`
`i . •
`
`i
`~'---f.... .
`.
`.
`.
`... L ..... j ....... ;.c;,..,l~----'.· ·-···',············--··· ,----·!----+---·'-;. --1
`.:~_.;• ...... J,-+--+--1
`
`!
`
`t
`
`!
`
`45 ·--·-·t· .. I
`SIGNATURE
`
`'
`.
`;
`. , • .
`.
`;
`:
`
`;
`
`T
`'
`
`i
`
`-
`
`;
`
`T l -·-······-· T-
`l
`•
`i
`;
`•
`\
`. ______ j
`~
`•
`I
`t
`-- ......... __ -__ -,T~~A·;-:;ToE-' .... .l ...... l ...... .l .... L .... ~· ........... _vCont!n_~~d_IE_f'B.f!.~---~-
`~~; '\]Jt'l"-·0--
`i I
`iiiscCosEii-i'a·AND-UNDERsTOOD-BY·---~IIi--- ... -·--7~'1'--------- .................. , .. ~DA-~T·Ec···----····· ........ ---··--·-···----!-·--···· --- · ··· \\\\ ~~----······· · ········--------------
`
`
`
`.
`
`~
`
`1;1.., 1
`I~; 11.2
`
`PROPRIETARY INFORMATION
`
`, 7. \'-;,
`___ ___ l_ ~1 ___ 0.2 __L __
`_ ____________ 1_o002 __ 36_98.274t- ____ ··
`-c_r -
`_
`..
`
`35
`
`.
`
`.
`
`•
`
`•
`.
`
`.
`
`t
`
`:
`
`;
`
`;
`'
`
`.
`
`•
`
`•
`
`:
`
`i
`.
`
`[ ~- .
`' ~'
`
`!
`
`T
`
`'
`.
`
`•
`
`-
`
`-
`
`,
`
`1
`
`' • i
`
`i
`.
`
`-; -
`
`~
`
`'{'
`1Q
`
`(9
`
`I
`
`'
`,
`
`·, , .
`
`. ,
`
`,
`
`'
`
`t
`
`T
`I
`
`1
`
`, c-::I"CEF-33=p1~lf8-iiji-±=tl ,,--
`--
`· · · .-.._'--- k · · · ·
`: r··---------.- -:··-Lt
`i
`i
`i
`:·
`: : ;
`i
`, .. __ _
`,
`·r··:-·T- .
`'
`--·- -· _, __ , ___ ,_
`'
`• '
`:
`; ~ i '
`401--!-----~---!--········''----'-·'·--c---•---~----i------~!----!---"··----··· __ ... L .... c ...... _ .. ;7 __ 1~f<~~/r~++---+''······'--j··+·-'··-i--f~--~Jc-i·-+··---·'--'-·····•'---l'--+---i··+
`i
`'
`l
`'
`'
`i
`'
`-...._
`i
`'
`'
`1---!----•'- .. J ...... c ...... ,'---·------'---:'-+-+·--l: ....... ;t . . +--"----:----c-'·--o'·-·····i·-··
`•
`' •
`"--....
`-+
`1 -+--!• -+--'··· .. .:... ..... c ... -•---:1 ..... +-·+·+--i- .. , ____ ,•_,: __ , _____ '._. _ _,1_ +·----·+ t'
`:'....,._
`!
`,
`'
`...
`' · ·
`' • :
`i
`I·
`• ..,__,
`i
`'
`451-~~~,~~~'-----l· __ l ....... : ..... l .... "--'---l' ...... ll ...... l ...... L ...... l .... ~~--'--~---·L ..... L. ..... L ... l.. ...... :··-· -·'--'. __ ·, ___ ;•;,~~~··---'-·----·'i ________ !, ______ ,· ___ li ........ ~c~oo,~~,~oo~d-~~·~Jp~age: ___ _
`~1)~
`\\\ \b\\J
`SIGNATURE
`DATE
`
`
`"DiscL:osED-TO-ANDUNDERSTOCio6v" ~~zy-.h-------·---·-·----··-----,-,D~A'r'cE· --,· ~·-h··-~---~-~---2·-----··-·-··-------····---·· ,__p_ .... R ...... o ..... p.--R-I_E.-T.: .. A._R ___ y ______ l_ N·---F···o ·····--R···--M···--·A··--··T·----1--o····N··--·
`
`v
`
`12
`
`
`
`BOOK
`
`16
`
`PAGE
`
`TITLE
`
`To P0J.o1'1M.
`I
`lpagek!
`
`c1/u; !1">
`rJ.'<...e.rd,.~.~n,.., shu:L.PROJECT 0X\.-If"VI0'll_ltulVle.- ~ d
`t-etb DATE
`?,r,z
`I l l l i ! '
`I I , T ' !J I
`' i ' 1~1 I
`I
`I i I
`I
`
`TITLE t 0 _p01-. ~-
`?page
`/C:/
`
`i
`'
`
`l
`
`l
`'
`I
`'
`5
`~~-j----!- ---!-----!~--:--
`1
`
`: .
`
`I
`: i
`.
`:
`15 ·- __ j_, ___ , ___ !~-"~----+ '·_
`:
`
`.l.
`
`'
`
`j
`!
`
`..
`
`20
`1----f-·'----c---"----+-
`
`Sample Name:
`Sample Type:
`Vial:
`Injection#:
`Injection Volume:
`Run Time:
`
`Date Acquired:
`Date Processed:
`
`ao.oo-
`
`" 60.00
`
`40.00
`
`20.00
`
`Dissolution Report ····----!----+----+----I
`
`:---
`1--~:c-----:- -+---+--_ .. 1
`
`i
`
`SAMPLE
`#ffi161-01_ OORE_pl-6.8_1 01-t ·1 ,
`·unk-noWn~ Stand6id
`1 :A, 1, 1 :A,2, 1 :A,3, 1 A,4, 1 :A,5,
`1,2,3,4,5
`10.00 ul
`6.0 Minutes
`
`INFORMATION
`Acquired By:
`Sample Set Name:
`Acq. Method Set:
`Processing Method:
`Channel Name:
`Proc. Chnl. Oeser.:
`
`Grishma
`ffi161_01_CORE _pl-¥3_8_111513
`Oxy rrorp hone_ OS _MS
`270_DS_PM_1
`ACQUITY TW ChA
`ACQUITY TW ChA 225nm
`
`11/15/2013 1 :10:36 PM EST, 11/15/2013 1:17:30 PM EST, 11/15/2013 1:24:24 PM EST,
`11/16/2013 10:39:29 AM EST, 11/16/201310:39:31 AM EST, 11/16/201310:39:32AM
`Dissolution Plot: Oxymorphone HCI
`
`'
`
`'
`.,
`
`•
`
`• QFactorA(72D.D,90 . .!-·"--··+---+-!
`i
`-ll
`:
`
`15
`
`'
`
`'
`
`I
`
`'
`
`'
`
`'
`
`'
`
`I
`
`'
`
`'
`
`'
`
`I
`
`'
`
`'
`
`'
`
`I
`
`'
`
`'
`
`'
`
`'
`
`I
`
`'
`
`'
`
`'
`
`.
`:
`!
`
`SYSTEM SUITABILITY AND BIAS CALCULATION SHEET
`
`Oxymorphone HCI ER Tab
`
`pH 6.8 phosphate
`
`Test-1
`
`wtof std I
`
`44.36 m~
`
`Pur~v cfstd
`
`99 5 % as '" baslS
`
`Sid Preparation:
`C:l =W<;i[•ili••;L• =1 -- ~ --
`
`'
`:
`
`'
`
`--•
`
`- - - - - J./
`BOOK
`PAGE
`dJ.,c;I'\I!.D-c\e>V\ ~kti.t.tPROJECT 0X~.-curpVLe9Yle. H.cl e...R _h:tb DATE
`i
`.
`'
`'
`:
`;
`' ,~ l
`I
`1~,'--'--'---'--'--c.__c_--'--..... ,_' __ , ___ ~'---+·-·t----+--
`i
`.
`.
`
`I
`
`i
`
`;
`
`.
`
`Y \RNOIR&O Analyllcai_HBR\Oxymorphone ER T ab\Analytical Resuns\Finished Produci\!Jissolul!on\PD161.Q1\PD16101_ CORE_pH6 e_DS _Bras Calculation_ 111613
`
`:
`
`..
`
`'
`
`.
`
`..
`
`..
`
`'
`
`'
`
`..
`
`•
`
`•
`
`•
`
`w ~--!f~~. ·~· - - ~=:;:~ ....
`1----+--+---f 1;_~ ____ ,'.- --t __
`
`2
`
`A
`
`2
`
`28
`
`41
`
`50
`
`58
`
`64
`
`68
`
`75
`
`26
`
`38
`
`48
`
`55
`
`61
`
`67
`
`74
`
`1
`
`35
`
`78
`
`82
`
`80
`
`BO
`
`84
`
`83
`
`Reported by User: Grishma ?hah (Grishma)
`Report Method: Dissolution Report
`Report Method ID 274468
`Page: 1 of 1
`
`Project Name: Oxymorphone HCI Tablets ....... +---c--+ -j
`Date Printed:
`11/16/2013 "-···+-:-- _:, --I
`3:41:45 PM US/Eastern -•---+·-C--i----1
`.
`:
`'
`;
`
`:
`
`I
`I
`I
`
`0~~\91U>- lice ER T~ )'!DIYlR--+--.L .... L- 1
`Li--#: Pb\61-0\ {~
`~ #- pH G ·'6" ~ieCciFo ,RuD.tf_,._
`Cnnr:l;h~* soornQ, 50~()} ~
`:Ip_:·\tlv:L
`.... . ..
`
`'
`
`I
`
`'
`
`I
`
`'
`
`'
`
`'
`
`'
`
`I
`
`'
`
`'
`
`---~--·-t·------;--·-~-----'{\
`
`i
`
`1
`
`Di~solved Pe_r«;:ent for Com!!Q!i_ent: Oxvmorphone HCI Chann~l: ACQUITY TUV ChA
`Injection T 60.0 min 120._~ min 180.0 min 240.0 min 3~~:0 min 3&0.0 min 480.0 min 600.0 min 72~
`Bath Vassel
`A
`1
`
`1
`
`26
`
`38
`
`48
`
`55
`
`61
`
`66
`
`73
`
`j
`f--+--+·-i,~-:'.- -+~ ~3-t-Ac-l--';t---;ct---::26:t--'~9~-l--48+--~56t--'-2l
`-,=,t-----=7=-, t----:7:::-, r- ---82
`----:-- 4 A
`4
`::+----::-+----:-::+
`30'----·+---+---j·,_ ... ';---+-- c:-5-t-A-1--:+~ -+--:+-~1----c:+----:+-cc
`·------a3
`;
`67
`74
`80
`5
`26
`39
`49
`56
`62
`! 6 ~ -t----:,:t---;t-----:2::17 r-~ .--ot--4-9 /---5--,7 f--- 63.1--,=,+----=7=5+-- ao c---.. ,
`;
`~an
`l----+--+-+---.t-,-·-'::-
`-62t--··-c,:=-7/-----:7c-4r--:7c9j ----:-.,:-1
`26
`39
`49
`56
`;,;_- -1 - - - j - -l--c,:::-,t----:.;:-,1 --c5=o+----=5=-a f-----:64+---::":f---::75+--:-ao: ------,.-
`:
`.
`1---+--··++---•--+ N
`+--+---+---::2,+---,,+--:-4,+---=55+--ccc61l
`66
`73
`78
`a2
`0
`::::-l--t--1---t-----::- --1---+--~1---:-::t----:-:::-f----:c:f-- -1---1
`'
`L
`;::
`: i
`1.2_L __ 1.0~
`RSD
`2.7 L___:2:_c.3i,____:2:_c.OL.
`1.8
`1.6
`1.5
`1.3
`i
`'
`I
`I :
`i .
`'
`i
`'
`40
`1---- ,-----+---+---'~-·--
`
`'
`
`.
`
`---~---'--
`.
`
`'
`
`!
`
`I
`
`•
`
`•
`
`~ . '
`
`i .
`
`. . ..
`
`. i
`
`·~
`
`..
`
`:
`
`'
`
`-
`
`.•
`
`•
`
`'
`
`'
`
`J
`
`'
`
`,
`
`• 3cp
`I
`.
`
`.
`
`~~ -ll·llb
`.
`.... )
`
`-.
`
`•
`
`.
`i . '
`
`'C-----•'····l--+·+·
`' -'
`
`i~ -
`:
`:
`. ..
`.
`~·
`401---J ...... J-+----''--:'-----·---c'----•'····-·i---f----i--+--+-···--····'-'----c'-·-·-·~--:•: ___ ~: __ f---!--+--i···'---~--L--"'--i--·i---1-·--j·-!:·c'---•----··'---•f-+"·-·t···:--i·
`'
`..
`'
`'
`..
`i
`
`i
`
`PROPRIETARY INFORMATION
`
`13
`
`
`
`I v 1!> ~ -
`
`BOOK
`
`ll'S
`PAGE
`
`ru to~- 19
`BOOK
`PAGE
`
`TITLE Tv pe.JJ-v'(Y'-\_ aUssoLu;,'on S~ PROJECT ID.x ~ i'V1.(l) yp hsvw...
`t-ed ~R. lrec.b DATI
`_E_~!!~!~-~~'!_t;.?!l!J:~q_; __ t ~---L-__ __-~--L-J----+----j-----~-----~---~--~-·-~-----!. -·----t----L ---l ·-·----~ ------i~---~--_:. ___ )_ --~-----i--·---1---· ---!----~-----~----~-~-----. ., ___ l_ --l----+·--
`System Suitability Summary Results
`-,
`Name: Ox mor hone HCI
`
`10
`
`Area
`
`I
`
`!
`
`USP
`USP
`5 :1
`RT
`Rate
`Narre
`Sample Narre
`Tailing
`Count
`f-----4----------------------~----------+-----~-----+----~--~
`f--1--+ _____ B_e_..g_s_td~-,._P_H_6._8 _____ 1-0_xy-__m_or_._p_h_on_e_HC_I-+_2_.2_7_3_~ 1907867
`77 43
`1.2
`.
`~-i9cJB650 , .. 7747_:_ u"
`Beg std_pH6.8
`, Oxymorphone HCI
`2.274
`2
`---+--- ------------------ -~----+-- - - - - - - - ------- I
`-+- -- ---~
`2____J
`I 775~--\- _12 _:
`Beg std_pH6.8
`I 2.275
`j 1908461
`1 Oxymorphone HCI
`--~_J
`~~-1_2_j
`5
`'T____j_1.2
`6
`8 L12 .
`
`' 1906222 I 775:··-~- ~}--
`! 1905541 i 7755 1 12
`~i:s::-~------ __ ~-~xymorp~on_e_:6i-j ~~~}-+ ~~1~ij ~~:: ; ~ ~
`
`I Oxymorphone HCI
`2.275
`--- - - - - : - - - - - - - - - - - - - j - - - - --
`_
`; Oxymorphone HCI
`2.27_5
`
`- -------~----- -.
`- --.
`-- ---,--------- -,----~-.- --------
`
`!
`
`____ ;
`
`.. ,.
`
`J
`
`. 1:
`
`xymorp one
`
`Mid std-2
`
`Mid std-2
`
`I s -
`Mid std-4
`
`,-------- ~---- - - - - - - - - - - -
`I
`I
`~
`I
`I
`10 I
`I
`I
`
`5
`
`1
`2
`
`3
`4
`
`5
`
`-- --~
`
`---· -------
`
`System Suitability Summary Results
`Name: O)(~moriJhOI}El HCI _
`I
`' I
`
`Narre
`
`!
`
`RT
`
`Area
`
`I
`
`Oxymorphone HCI
`
`I
`
`Oxymorphone HCI
`
`2.273
`2.274
`-
`Oxymorphone HCI
`2.275
`2.274
`Oxymorphone HCI
`I Oxymorphone HCll 2.273
`
`1907867
`1908650
`
`190846_1_j_
`1909122 I
`1908573 I
`
`Sample Narre
`
`Beg std pH6.8
`
`Beg std pH6.8
`Beg std pH6.8
`
`Beg std pH6.8
`Beg std_pH6.8
`
`------------ --------- --------- -------- - --- ---- -~---- ___ ;. -·. --~- ----...:- - __ , __ -· _, ___ ·- -~-
`
`20 ==~"~1~~==-=~~~t~~-El~E~)I:;·i-~~~:-F~Qt~llil~:~=:~1~;:---~~t-T::::-_-c ___ .. __ --__ ·,-__ -'-----·-----------+--'----c---1
`-~ttJ:::r:~:~:~--:_=~~;L}!~t__':j~=T~:I:a~·Ci:···:_c__JYJ:!ii::~::;;n_:_~--~--T_:~::t=t·I::·~~==·=::~:=====~~L~::::::
`
`.
`
`-
`
`.
`
`.
`
`.
`
`.
`
`'
`
`.
`
`.
`
`-
`
`... _____ ···------'.------~--
`
`15
`
`1
`
`----~-
`
`+--+
`...... --~---- --
`1-
`--!
`9
`I------t·--
`J-~~---
`20 --~---- 12
`
`Mid std-4
`End std
`
`End std
`
`-1_~13 __ --l----
`-~
`14
`'
`-r---1--5 -+I~
`25 -r--Me;;:; ·1
`l-
`--1 Std. Dev.'
`t---- --- --
`!-
`' %RSD ;
`
`-
`
`Oxymorphone HCI
`Oxymorphone HCI
`t-~
`Oxymorphone HCI
`
`--------- - - -
`
`Oxymorphone HCI
`
`2.272
`
`2.275
`
`-
`
`2.274
`2.274
`
`-
`
`------ - - -
`
`1902274
`
`1.1
`1 .1
`
`7733
`7758
`1902173
`+-------i-
`1899863 . 7759
`1.1
`1899658l_~760Tu-
`I 1.2
`, 1905413 I 7751
`2.274
`--:-------
`o.oo1 -l32s?.o64-~
`---------~~v" -------- ~--- ____ J_ o.o
`-·-
`o.2
`-··----·-------·---~-·---------- ------·- ,-----. - , -- ~--~·------------- --·----- ~---·;·--
`• _L, ___ ,_ : ...•... : ••• c .... : .... ' ............ !. .. : ....... '--... , ......... c. ---i-- +--i--
`.-- : ...... : ...... : ...... -· -.. .! ··-- .... -.. : ....... j' ..... -+--+--i----·'· _,____,-- _, ---+ -+-
`· ____ : _____ ;_L .. __ j ___ c __ , ____ "---- . ·"······'---·····+--·+··'---
`L ~ --~ ~--~~------~---· __ ; ____ L ___ -~---._.1 ____ ~-----~ ___ ~ ___ ~-_____ ~ ·-·--·-·-____ ! ______ ; _____ ~--
`
`--+-·--+-·······'----~ -----·•-- ---· ---•----~--... c ---i---·
`------·-. ---· ________ J-----~--~----
`
`40t-:----! ---t --+--+-+---·---+- +--+--+- !--+--+-- ·---j----"--i -